ArticleOncotarget2017

The anti-ErbB2 antibody H2-18 and the pan-PI3K inhibitor GDC-0941 effectively inhibit trastuzumab-resistant ErbB2-overexpressing breast cancer.

Lingfei Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.